Nanogam (Human Normal Immunoglobulin)

Human normal immunoglobulin, the active ingredient in Nanogam, is an immunoglobulin presented as a solution for injection for intravenous use. It replaces deficient IgG antibodies and is employed to prevent infections in patients with primary or secondary antibody deficiencies.

GNH USA supplies Nanogam as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide. The product is manufactured in the European Union under strict quality standards. It is distributed globally to support immune‑deficient patient care.

Nanogam is used in immunoglobulin replacement therapy to restore antibody levels in various immune‑deficient conditions.

Primary immunodeficiency diseases: provides IgG replacement to reduce frequency and severity of infections. Secondary immunodeficiency: supplies pooled antibodies to support immune function in patients with acquired deficiency such as chemotherapy‑induced hypogammaglobulinemia. Prevention of infections in patients with antibody deficiency: enhances host defense, lowering risk of bacterial and viral infections.

Nanogam may be associated with infusion‑related and immunologic adverse reactions.

Common Side Effects: - Infusion‑related reactions such as fever, chills, headache, or flushing. - Mild allergic manifestations including rash, pruritus, or urticaria. - Nausea, vomiting, or abdominal discomfort. - Fatigue or transient dizziness during or after infusion.

Serious or Rare Side Effects: - Anaphylaxis or severe hypersensitivity reactions. - Hemolytic anemia due to anti‑blood group antibodies. - Thromboembolic events including deep‑vein thrombosis or pulmonary embolism. - Acute renal failure or aseptic meningitis. - Severe hypotension or cardiovascular collapse.

Before initiating Nanogam therapy, clinicians should evaluate patient history and monitor for potential complications. - Assess baseline IgG levels: determine need for replacement therapy. - Monitor for infusion reactions: start at a slower rate and observe vital signs. - Adjust infusion rate in patients with cardiovascular disease or fluid overload risk. - Use caution in individuals with known IgA deficiency and anti‑IgA antibodies. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Nanogam can interact with other agents that affect immune function or blood coagulation.

Major Interactions (Avoid): - Concomitant administration of live vaccines: may reduce vaccine efficacy. - Use with other immunoglobulin products: risk of immunoglobulin overload. - Concurrent high‑dose anticoagulants: increased bleeding risk due to volume load.

Moderate Interactions (Monitor Closely): - Corticosteroids: may augment infection risk. - Cytotoxic chemotherapy: may alter immune response to IVIG. - Inactivated vaccines: monitor serologic response after administration.